94 related articles for article (PubMed ID: 24845030)
21. Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer?
Inno A; Di Salvatore M; Cenci T; Martini M; Orlandi A; Strippoli A; Ferrara AM; Bagalà C; Cassano A; Larocca LM; Barone C
Clin Colorectal Cancer; 2011 Dec; 10(4):325-32. PubMed ID: 21729677
[TBL] [Abstract][Full Text] [Related]
22. Indirect Down-regulation of Tumor-suppressive
Saeki N; Saito A; Sugaya Y; Amemiya M; Sasaki H
Cancer Genomics Proteomics; 2018; 15(5):413-420. PubMed ID: 30194082
[TBL] [Abstract][Full Text] [Related]
23. [The role of KRAS gene mutation testing in colorectal cancer--a predictive biomarker of response to EGFR inhibitors therapy].
Rako I; Jakić-Razumović J; Caban D; Sertić J; Katalinić D; Golem H; Plestina S
Lijec Vjesn; 2011; 133(11-12):403-7. PubMed ID: 22329297
[TBL] [Abstract][Full Text] [Related]
24. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.
Tol J; Dijkstra JR; Klomp M; Teerenstra S; Dommerholt M; Vink-Börger ME; van Cleef PH; van Krieken JH; Punt CJ; Nagtegaal ID
Eur J Cancer; 2010 Jul; 46(11):1997-2009. PubMed ID: 20413299
[TBL] [Abstract][Full Text] [Related]
25. Integrative genomics identifies LMO1 as a neuroblastoma oncogene.
Wang K; Diskin SJ; Zhang H; Attiyeh EF; Winter C; Hou C; Schnepp RW; Diamond M; Bosse K; Mayes PA; Glessner J; Kim C; Frackelton E; Garris M; Wang Q; Glaberson W; Chiavacci R; Nguyen L; Jagannathan J; Saeki N; Sasaki H; Grant SF; Iolascon A; Mosse YP; Cole KA; Li H; Devoto M; McGrady PW; London WB; Capasso M; Rahman N; Hakonarson H; Maris JM
Nature; 2011 Jan; 469(7329):216-20. PubMed ID: 21124317
[TBL] [Abstract][Full Text] [Related]
26. The tumor-suppressor gene LZTS1 suppresses colorectal cancer proliferation through inhibition of the AKT-mTOR signaling pathway.
Zhou W; He MR; Jiao HL; He LQ; Deng DL; Cai JJ; Xiao ZY; Ye YP; Ding YQ; Liao WT; Liu SD
Cancer Lett; 2015 Apr; 360(1):68-75. PubMed ID: 25667121
[TBL] [Abstract][Full Text] [Related]
27. Coexpression of biological key modulators in primary colorectal carcinomas and related metastatic sites: implications for treatment with cetuximab.
Barbier A; Domont J; Magné N; Goldmard JL; Genestie C; Hannoun C; Vaillant JC; Bellanger A; Khayat D; Capron F; Spano JP
Bull Cancer; 2010 Feb; 97(2):E9-E15. PubMed ID: 20085858
[TBL] [Abstract][Full Text] [Related]
28. The genomic landscape of response to EGFR blockade in colorectal cancer.
Bertotti A; Papp E; Jones S; Adleff V; Anagnostou V; Lupo B; Sausen M; Phallen J; Hruban CA; Tokheim C; Niknafs N; Nesselbush M; Lytle K; Sassi F; Cottino F; Migliardi G; Zanella ER; Ribero D; Russolillo N; Mellano A; Muratore A; Paraluppi G; Salizzoni M; Marsoni S; Kragh M; Lantto J; Cassingena A; Li QK; Karchin R; Scharpf R; Sartore-Bianchi A; Siena S; Diaz LA; Trusolino L; Velculescu VE
Nature; 2015 Oct; 526(7572):263-7. PubMed ID: 26416732
[TBL] [Abstract][Full Text] [Related]
29. PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer.
Prenen H; De Schutter J; Jacobs B; De Roock W; Biesmans B; Claes B; Lambrechts D; Van Cutsem E; Tejpar S
Clin Cancer Res; 2009 May; 15(9):3184-8. PubMed ID: 19366826
[TBL] [Abstract][Full Text] [Related]
30. Biomarkers for predicting the efficacy of anti-epidermal growth factor receptor antibody in the treatment of colorectal cancer.
Okada Y; Miyamoto H; Goji T; Takayama T
Digestion; 2014; 89(1):18-23. PubMed ID: 24458108
[TBL] [Abstract][Full Text] [Related]
31. Circulating tumor cells as a longitudinal biomarker in patients with advanced chemorefractory, RAS-BRAF wild-type colorectal cancer receiving cetuximab or panitumumab.
Musella V; Pietrantonio F; Di Buduo E; Iacovelli R; Martinetti A; Sottotetti E; Bossi I; Maggi C; Di Bartolomeo M; de Braud F; Daidone MG; Cappelletti V
Int J Cancer; 2015 Sep; 137(6):1467-74. PubMed ID: 25704501
[TBL] [Abstract][Full Text] [Related]
32. Beyond KRAS status and response to anti-EGFR therapy in metastatic colorectal cancer.
Perkins G; Pilati C; Blons H; Laurent-Puig P
Pharmacogenomics; 2014 May; 15(7):1043-52. PubMed ID: 24956256
[TBL] [Abstract][Full Text] [Related]
33. [Predictive factors of response to anti-EGFR treatments in colorectal cancer].
Lièvre A; Laurent-Puig P
Bull Cancer; 2008 Jan; 95(1):133-40. PubMed ID: 18230579
[TBL] [Abstract][Full Text] [Related]
34. MicroRNA profiling predicts survival in anti-EGFR treated chemorefractory metastatic colorectal cancer patients with wild-type KRAS and BRAF.
Mosakhani N; Lahti L; Borze I; Karjalainen-Lindsberg ML; Sundström J; Ristamäki R; Osterlund P; Knuutila S; Sarhadi VK
Cancer Genet; 2012 Nov; 205(11):545-51. PubMed ID: 23098991
[TBL] [Abstract][Full Text] [Related]
35. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
Erjala K; Sundvall M; Junttila TT; Zhang N; Savisalo M; Mali P; Kulmala J; Pulkkinen J; Grenman R; Elenius K
Clin Cancer Res; 2006 Jul; 12(13):4103-11. PubMed ID: 16818711
[TBL] [Abstract][Full Text] [Related]
36. Expression of EGFR, Her2 predict lymph node metastasis (LNM)-associated metastasis in colorectal cancer.
Lu Y; Jingyan G; Baorong S; Peng J; Xu Y; Cai S
Cancer Biomark; 2012; 11(5):219-26. PubMed ID: 23220854
[TBL] [Abstract][Full Text] [Related]
37. The prognostic role of ephrin A2 and endothelial growth factor receptor pathway mediators in patients with advanced colorectal cancer treated with cetuximab.
Strimpakos A; Pentheroudakis G; Kotoula V; De Roock W; Kouvatseas G; Papakostas P; Makatsoris T; Papamichael D; Andreadou A; Sgouros J; Zizi-Sermpetzoglou A; Kominea A; Televantou D; Razis E; Galani E; Pectasides D; Tejpar S; Syrigos K; Fountzilas G
Clin Colorectal Cancer; 2013 Dec; 12(4):267-274.e2. PubMed ID: 24050852
[TBL] [Abstract][Full Text] [Related]
38. Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer.
Park JH; Han SW; Oh DY; Im SA; Jeong SY; Park KJ; Kim TY; Bang YJ; Park JG
Cancer Chemother Pharmacol; 2011 Oct; 68(4):1045-55. PubMed ID: 21340604
[TBL] [Abstract][Full Text] [Related]
39. HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer.
Takegawa N; Yonesaka K; Sakai K; Ueda H; Watanabe S; Nonagase Y; Okuno T; Takeda M; Maenishi O; Tsurutani J; Satoh T; Okamoto I; Nishio K; Tamura T; Nakagawa K
Oncotarget; 2016 Jan; 7(3):3453-60. PubMed ID: 26657506
[TBL] [Abstract][Full Text] [Related]
40. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
Lee J; Lee I; Han B; Park JO; Jang J; Park C; Kang WK
J Natl Cancer Inst; 2011 Apr; 103(8):674-88. PubMed ID: 21398618
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
